Does Alnylam Pharmaceuticals (ALNY) Have the Potential to Generate Strong Long-Term Growth?

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund (Investor Shares) returned 13.29% (net of fees) in the quarter, compared to the Russell Midcap Growth Index’s 18.20% return. Stock selection in the Industrials and Information Technology sectors negatively impacted the performance, while holdings in the Financials sector contributed. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its second-quarter 2025 investor letter, Parnassus Mid Cap Growth Fund highlighted stocks such as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) discovers and commercializes therapeutics based on ribonucleic acid interference. The one-month return of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was 1.34%, and its shares gained 66.94% of their value over the last 52 weeks. On September 24, 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock closed at $458.37 per share, with a market capitalization of $60.083 billion.

Parnassus Mid Cap Growth Fund stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in its second quarter 2025 investor letter:

“We also reinitiated a position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The company’s innovative platform and expanding product portfolio in areas like cardiomyopathy should enable Alnylam to generate robust growth. Alnylam is a pioneer in RNA interference therapeutics, a novel class of medicines. With innovative products and a healthy cash balance, Alnylam provides high-quality biotech exposure. The company has the potential to generate strong long-term growth due to an expanding product portfolio in areas like cardiomyopathy.”

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 58 hedge fund portfolios held Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) at the end of the second quarter, which was 59 in the previous quarter. While we acknowledge the risk and potential of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and shared ClearBridge All Cap Growth Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.